Supporting the Leukemia and Lymphoma Society of Canada
This week, Clementine Fields will be supporting the Leukemia & Lymphoma Society of Canada by donating 10% of sales in honour of the 10th anniversary of Light the Night, a lantern-lit walk in support and memory of those affected by blood cancer.
We reached out to Campaign manager, Angela Power-Rose to get more information on why this charity is an important one and how they give back to those affected.
1/ Who started the Leukemia & Lymphoma Society of Canada in Canada? The organization was founded in Toronto in 1955 by five women concerned with the lack of focus on leukemia research. We are now affiliated with the LLS in the USA, but remain a registered charity in Canada.
2/ How does LLSC affect peoples’ lives who have been diagnosed with leukemia and lymphoma? LLSC is extremely proud of the important work our staff and volunteers do to support thousands of patients and their families who are facing the diagnosis of a blood cancer, to help them survive and hopefully, be cured.
Patient support includes 15 Support Groups functioning across Canada, the Trish Greene Back to School program which helps educators and parents ensure children have the optimal back to school experience after cancer treatment. As well, patient education programs which cover a wide spectrum of topics from disease-specific (i.e. Understanding Leukemia) to coping mechanisms (i.e. strategies to help with stress & anxiety) to research advances (i.e. The Future of CLL Treatment in Canada) to survivorship issues (i.e. Dealing with Treatment-Related Infertility). We also provide one-on-one information & support to patients/caregivers, among other programs and connections.
3/ Does the money raised go towards research in developing drugs such as Gleevec? Our research track record demonstrates the depth of our commitment to our mission. What's more, many of the blood cancer treatment and therapies we've funded have gone on to benefit patients who have other types of cancer.
Highlights of recent successes and ongoing studies include Gleevec, which is a revolutionary drug. Since its approval by the Food and Drug Administration in 2001, Gleevec has become a standard first-line therapy for newly diagnosed Chronic Myeloid Leukemia patients. This groundbreaking treatment, which was funded by LLS, has nearly doubled the survival rate for people with Chronic Myeloid Leukemia to 95 percent.
Like Gleevec, the drugs Sprycel and Tasigna were also advanced by LLS-funded researchers. Both drugs benefit people with Chronic Myeloid Leukemia. Along with Gleevec, they're helping chronic phase patients survive many years with good quality of life.
LLSC's Therapy Acceleration Program, launched in 2007, helps speed blood cancer research along during what can be an otherwise slow-moving process. It's helped bring more treatments to more patients faster.
4/ How much of every dollar raised goes towards the actual charity?
Our strategy to achieve the mission is based on three areas of focus: research, patient support and advocacy. In 2013 we spent over $4.1 million on public education programs, over $2.8 million on patient support and over $1.8 million on research.
5/ Why is LLS important to families of patients?
When a patient is diagnosed with blood cancer, the whole family is affected. The LLSC is there for patients from diagnosis and throughout the entire cancer journey. We provide free programs and resources for patients and their families to educate, support and advocate for their needs while coping with their disease.